These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 24544598)

  • 1. A comparative study of 6-diazo-5-oxo-L-norleucine and O-diazoacety-L-serine on sarcoma 180.
    CLARKE DA; REILLY HC; STOCK CC
    Antibiot Chemother (Northfield); 1957 Dec; 7(12):653-71. PubMed ID: 24544598
    [No Abstract]   [Full Text] [Related]  

  • 2. Inhibition of uric acid biosynthesis in birds by o-diazoacetyl-L-serine (azaserine) and 6-diazo-5-oxo-L-norleucine (DON).
    KRAKOFF IH; KARNOFSKY DA
    Am J Physiol; 1958 Oct; 195(1):244-50. PubMed ID: 13583156
    [No Abstract]   [Full Text] [Related]  

  • 3. The effect of azaserine and 6-diazo-5-oxo-L-norleucine on the biosynthesis of inosinic acid de novo.
    BUCHANAN JM
    Tex Rep Biol Med; 1957; 15(1):148-53. PubMed ID: 13409287
    [No Abstract]   [Full Text] [Related]  

  • 4. Biosynthesis of the purines. XV. The effect of aza-L-serine and 6-diazo-5-oxo-L-norleucine on inosinic acid biosynthesis de novo.
    LEVENBERG B; MELNICK I; BUCHANAN JM
    J Biol Chem; 1957 Mar; 225(1):163-76. PubMed ID: 13416227
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects on DON (6-diazo-5-oxo-L-norleucine) and azaserine on the sand-dollar embryo.
    KARNOFSKY DA; BEVELANDER G
    Proc Soc Exp Biol Med; 1958 Jan; 97(1):32-7. PubMed ID: 13518172
    [No Abstract]   [Full Text] [Related]  

  • 6. Concentrative uptake of 6-diazo-5-oxo-L-norleucine by sarcoma 180, liver and muscle in vivo.
    JACQUEZ JA
    Proc Soc Exp Biol Med; 1958 Dec; 99(3):611-3. PubMed ID: 13614439
    [No Abstract]   [Full Text] [Related]  

  • 7. Potential anti-cancer agents--II. A proposed mechanism for the anti-cancer action of L-azaserine and 6-diazo-5-oxo-L-norleucine.
    BAKER BR
    Biochem Pharmacol; 1959 Sep; 2():161-7. PubMed ID: 13795976
    [No Abstract]   [Full Text] [Related]  

  • 8. 6-Diazo-5-oxo-L-norleucine, a new tumor-inhibitory substance. V. Microbiologic studies of mode of action.
    MAXWELL RE; NICKEL VS
    Antibiot Chemother (Northfield); 1957 Feb; 7(2):81-9. PubMed ID: 24544268
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of 6-diazo-5-oxo-L-norleucine on the incorporation of precursors into nucleic acids.
    BARCLAY RK; GARFINKEL E; PHILLIPPS MA
    Cancer Res; 1962 Aug; 22():908-14. PubMed ID: 13864924
    [No Abstract]   [Full Text] [Related]  

  • 10. Active transport of O-diazoacetyl-L-serine and 6-diazo-5-oxo-L-norleucine in Ehrlich ascites carcinoma.
    JACQUEZ JA
    Cancer Res; 1957 Oct; 17(9):890-6. PubMed ID: 13472680
    [No Abstract]   [Full Text] [Related]  

  • 11. Resistance in L1210 ascites without change in concentrative uptake of o-diazoacetyl-L-serine or 6-diazo-5-oxo-L-norleucine.
    JACQUEZ JA; HUTCHISON DJ
    Cancer Res; 1959 May; 19(4):397-401. PubMed ID: 13652124
    [No Abstract]   [Full Text] [Related]  

  • 12. 6-Diazo-5-oxo-L-norleucine, a new tumor-inhibitory substance. I. Biologic studies.
    COFFEY GL; EHRLICH J; FISHER MW; HILLEGAS AB; KOHBERGER DL; MACHAMER HE; RIGHTSEL WA; ROEGNER FR
    Antibiot Chemother (Northfield); 1956 Aug; 6(8):487-97. PubMed ID: 24544086
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of combinations of azaserine and of 6-diazo-5-oxo-L-norleucine with purine analogs and other antimetabolites on the growth of two mouse mammary carcinomas.
    TARNOWSKI GS; STOCK CC
    Cancer Res; 1957 Nov; 17(10):1033-9. PubMed ID: 13489704
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of 6 diazo 5 oxo l-norleucine on the rat litter in utero.
    THIERSCH JB
    Proc Soc Exp Biol Med; 1957 Jan; 94(1):33-5. PubMed ID: 13400863
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy of 6-diazo-5-oxo-L-norleucine and N-[N-gamma-glutamyl-6-diazo-5-oxo-norleucinyl]-6-diazo-5-oxo-norleucine against experimental tumors in conventional and nude mice.
    Ovejera AA; Houchens DP; Catane R; Sheridan MA; Muggia FM
    Cancer Res; 1979 Aug; 39(8):3220-4. PubMed ID: 572261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alterations in calcium metabolism in cancer patients treated with 6-diazo-5-oxo-L-norleucine.
    MAGILL GB; MYERS WP
    Proc Soc Exp Biol Med; 1956 Nov; 93(2):314-8. PubMed ID: 13379496
    [No Abstract]   [Full Text] [Related]  

  • 17. Suppression of uric acid synthesis in the gouty human by the use of 6-diazo-5-oxo-L-norleucine.
    GRAYZEL AI; SEEGMILLER JE; LOVE E
    J Clin Invest; 1960 Mar; 39(3):447-54. PubMed ID: 13829149
    [No Abstract]   [Full Text] [Related]  

  • 18. The effect of 6-diazo-5-oxo-1-norleucine (DON) on pregnancy.
    JACKSON D; ROBSON JM; WANDER AC
    J Endocrinol; 1959 Mar; 18(2):204-7. PubMed ID: 13641559
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacological and initial therapeutic observations on 6-diazo-5-oxo-1-norleucine (DON) in human neoplastic disease.
    MAGILL GB; MYERS WP; REILLY HC; PUTNAM RC; MAGILL JW; SYKES MP; ESCHER GC; KARNOFSKY DA; BURCHENAL JH
    Cancer; 1957; 10(6):1138-50. PubMed ID: 13489662
    [No Abstract]   [Full Text] [Related]  

  • 20. Variation in resistance patterns in different neoplasms.
    POTTER M
    Ann N Y Acad Sci; 1958 Dec; 76(3):630-42. PubMed ID: 13627890
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.